Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sensitive PCR Test Detects Early Stage Lyme Disease

By LabMedica International staff writers
Posted on 19 Apr 2021
A highly sensitive blood test detects the bacteria that causes Lyme disease in early stages of the infection, when treatment can prevent the development of serious or fatal consequences of the chronic disease.

The successful treatment of Lyme disease (LD) is contingent on accurate diagnosis. However, current laboratory detection assays lack sensitivity in the early stages of the disease. Since delayed diagnosis of LD can result in high healthcare costs and great suffering to the patient, new highly sensitive tests are needed.

In this regard, investigators at the University of Leicester (United Kingdom) developed an internally controlled quantitative PCR test that targeted the multicopy terminase large subunit (terL) gene encoded by prophages that are only found in LD-causing bacteria. A prophage is a bacteriophage genome inserted and integrated into the circular bacterial DNA chromosome or present as an extrachromosomal plasmid. This is a latent form of a phage, in which the viral genes are present in the bacterium without causing disruption of the bacterial cell.

The newly developed Ter-qPCR test was based on the polymerase chain reaction (PCR), which amplifies small amounts of specific genetic material so that it can be detected. To increase the sensitivity of the test for detection of Borrelia burgdorferi, the causative agents of Lyme disease, the investigators adapted it to be specific for the prophage terL gene. The terL protein helps phages package their DNA.

The diagnostic potential of the Ter-qPCR test was evaluated using a set of blood and serum samples collected from healthy volunteers and individuals who were clinically diagnosed with Lyme disease. Results revealed that the detection limit of the Ter-qPCR test was estimated to be 22 copies, the equivalent of one bacterial cell in a bacteria spiked blood sample. Furthermore, significant quantitative differences were observed in terms of the amount of terL detected in healthy individuals and patients with either early or late Lyme disease.

"Early diagnosis of Lyme disease is absolutely vital in reducing suffering, because early Lyme can be treated, but late Lyme is very difficult to treat," said first author Dr. Jinyu Shan, a researcher in the department of respiratory sciences at the University of Leicester. "Current tests cannot typically detect the low numbers of bacteria in early-stage patient blood samples. Our goal was to design a highly sensitive test to help doctors to identify Lyme disease as early as possible. We are currently working with a commercial partner, and investigating regulatory issues and the potential for a clinical trial for this technology."

The Ter-qPCR test was described in the March 15, 2021, online edition of the journal Frontiers in Microbiology.

Related Links:
University of Leicester


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.